Lite Strategy (LITS) Registration Filing summary

Company overview and business model

• Operates as a pharmaceutical company with a portfolio of drug candidates, including voruciclib, an oral CDK9 inhibitor.

• Recently adopted a Litecoin treasury strategy, intending to use proceeds to acquire Litecoin as a primary reserve asset.

• Believes this approach will diversify reserves, enhance capital efficiency, and align with emerging financial technologies.

Financial performance and metrics

• Classified as a smaller reporting company, with less than $250 million in market value of shares held by non-affiliates or less than $100 million in annual revenues.

• 32,367,236 shares of common stock outstanding before the offering; 39,375,773 shares after full exercise of all warrants.

Use of proceeds and capital allocation

• Will not receive proceeds from the sale of shares by selling stockholders.

• May receive up to $394,000 from Pre-Funded Warrants, $6 million from Asset Manager Warrants, $1.8 million from Strategic Advisor Warrants, and $4.8 million from Placement Agent Warrants if fully exercised.

• Intends to use all proceeds from warrant exercises to purchase Litecoin.